Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Maxona Pharmaceuticals Announces MAX-OO1 Phase 1 Clinical Program Results
Details : MAX-001 (Nefopam HCl) is a non-opioid, non-NSAID oral therapy, which is currently being evaluated for the treatment of patients with acute and chronic pain.
Product Name : MAX-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Maxona Pharmaceuticals Exits Stealth, Advances MAX-001 First-To-Market Candidate
Details : The company's initial focus is on advancing MAX-001 as a safe and highly effective non-opioid option for the treatment of acute and chronic pain.
Product Name : MAX-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable